PT Metro Healthcare Indonesia Tbk (CARE.JK)
- Previous Close
220.00 - Open
222.00 - Bid 220.00 x --
- Ask 224.00 x --
- Day's Range
220.00 - 232.00 - 52 Week Range
56.00 - 232.00 - Volume
20,262,300 - Avg. Volume
21,798,007 - Market Cap (intraday)
7.315T - Beta (5Y Monthly) -0.64
- PE Ratio (TTM)
-- - EPS (TTM)
-2.64 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PT Metro Healthcare Indonesia Tbk owns, operates, and manages hospitals in Indonesia. It provides the management of hospitals, clinics, treatment hall, polyclinics and other medical centers, and physical medicine and trading; private polyclinics; trading, industry, development and services; professional, scientific, technical, financial, and investment activities; transportation, industry, workshop, forestry and agriculture; health support facilities, and health support services; and real estate and retail trading. It also provides health and management consulting services, as well as invests in subsidiaries. The company was founded in 2015 and is based in Tangerang, Indonesia. PT Metro Healthcare Indonesia Tbk is a subsidiary of PT Metro Healthcare International.
www.metrohealthcareindonesia.co.id833
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CARE.JK
View MorePerformance Overview: CARE.JK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is IDX COMPOSITE (^JKSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CARE.JK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CARE.JK
View MoreValuation Measures
Market Cap
7.32T
Enterprise Value
7.80T
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.21
Price/Book (mrq)
2.45
Enterprise Value/Revenue
24.75
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.68%
Return on Assets (ttm)
-0.63%
Return on Equity (ttm)
-2.87%
Revenue (ttm)
315.19B
Net Income Avi to Common (ttm)
-87.23B
Diluted EPS (ttm)
-2.64
Balance Sheet and Cash Flow
Total Cash (mrq)
449.98B
Total Debt/Equity (mrq)
31.29%
Levered Free Cash Flow (ttm)
-289.54B